featured-image

The CEO of Novo Nordisk was questioned about the high cost in the U.S. of Wegovy and Ozempic, the wildly popular diabetes and weight-loss drugs.

Lars Jorgensen said pharmacy benefit managers are mostly to blame. NBC News' Stephanie Gosk reports. Sept.



24, 2024.

Back to Entertainment Page